Advertisement
Advertisement
VRDN
Viridian Therapeutics, Inc. Common Stock
17.73
USDSponsored
+0.69
+4.07%
May 14, 10:05 UTC -4
Open
VRDN Earnings Reports
Positive Surprise Ratio
VRDN beat 24 of 40 last estimates.
60%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$9.83M
/-$1.08
Implied change from Q1 26 (Revenue/ EPS)
+6874.73%
/+20.00%
Implied change from Q2 25 (Revenue/ EPS)
+13012.49%
/+8.00%
Viridian Therapeutics, Inc. Common Stock earnings per share and revenue
On May 05, 2026, VRDN reported earnings of -0.90 USD per share (EPS) for Q1 26, beating the estimate of -1.11 USD, resulting in a 19.37% surprise. Revenue reached 141.00 thousand, compared to an expected 28.05 thousand, with a 402.67% difference. The market reacted with a +33.36% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -1.08 USD, with revenue projected to reach 9.83 million USD, implying an increase of 20.00% EPS, and increase of 6874.73% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
CorMedix Inc.
Report Date
May 14, 2026 For Q1 26
Estimate
$0.37
Actual
$0.43
Surprise
+15.59%
Invivyd, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.13
Surprise
-73.80%
REGENXBIO Inc.
Report Date
May 14, 2026 For Q1 26
Estimate
-$1.36
Actual
-$1.72
Surprise
-25.94%
Autolus Therapeutics plc - ADR
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.26
Actual
-$0.27
Surprise
-2.94%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+217.65%
Immunic, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.93
Actual
-$1.08
Surprise
-16.03%
Humacyte, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.11
Actual
-$0.09
Surprise
+24.05%
Pelthos Therapeutics Inc.
Report Date
May 14, 2026 For Q1 26
Estimate
-$3.34
Actual
-$3.09
Surprise
+7.55%
Dogwood Therapeutics, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.26
Actual
-$0.15
Surprise
+42.70%
Hyperion DeFi, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
$0.74
Actual
-$0.82
Surprise
-210.13%
FAQ
What were Viridian Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Viridian Therapeutics, Inc. Common Stock reported EPS of -$0.90, beating estimates by 19.37%, and revenue of $141.00K, 402.67% above expectations.
How did the market react to Viridian Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 33.36%, changed from $14.06 before the earnings release to $18.75 the day after.
When is Viridian Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for Viridian Therapeutics, Inc. Common Stock's next earnings report?
Based on 10
analysts, Viridian Therapeutics, Inc. Common Stock is expected to report EPS of -$1.08 and revenue of $9.83M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement